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Objectives: Systemic Lupus Erythematosus (SLE) is an autoimmune disease, char-
acterized by periods of remissions and flares, with significant clinical and economic 
burden. The primary study objective was to estimate the 1-year direct medical cost 
for adult patients with active, autoantibody-positive SLE in Greece. MethOds: This 
is a national, multi-centre, retrospective study. Data were abstracted from patient 
records in 6 hospital centers specialized in SLE management. Starting with the 
patient with the most recent visit, patients with consecutive visits (backwards in 
time) were considered for inclusion, provided they met specific criteria. In order to 
estimate costs per disease severity, a stratification criterion was applied. Patient 
data were collected for a 1-year period starting from the inclusion date (January 
-September 2011) and moving forward. Data included patient characteristics and 
health care resource utilization. In addition, all SLE patients fulfilling the inclu-
sion criteria and followed-up in the participating centers during a 3-month ret-
rospective period were recorded. For cost calculation, official 2013 list prices were 
used. Results: 215 patients (30% severe according to the stratification criterion) 
were included in the study. Mean direct medical costs were estimated at € 1,225 
for patients with non-severe and at € 3,741 for patients with severe active SLE. 
Laboratory and imaging tests, medicines, physicians’ visits, and hospitalization 
costs represented 10.5%, 51.7%, 1.2%, 36.5% of mean cost respectively. Costs were 
statistically significantly higher for severe SLE patients. The total number of patients 
visiting the participating clinical sites during a 3-month period was 318 (19% with 
severe SLE). The weighted mean annual direct medical cost of SLE in Greece was esti-
mated at € 1,703. cOnclusiOns: Direct medical cost of SLE in Greece is significant, 
especially for patients with severe disease. An estimation of indirect costs would 
provide a comprehensive picture of the societal burden of the disease.
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Objectives: Immune thrombocytopenia (ITP) is characterized by isolated thrombo-
cytopenia with no underlying cause. It manifests clinically as mucocutaneous bleed-
ing caused by decreased platelets. Recently, two thrombopoietin receptor-agonists 
have emerged as an important therapeutic options: romiplostim and eltrombopag. 
Since these medications have different mode of administration, safety and effi-
cacy profiles, the present study was carried out in an attempt to investigate which 
drug would be more cost-effective in the Brazilian setting. The objective was to 
perform an economic analysis evaluating the cost per response of romiplostim 
versus eltrombopag in adult patients with chronic ITP and refractory to other treat-
ments as corticosteroids and immunoglobulins in Brazil health care private sys-
tem. MethOds: Two economic analyses were performed in order to study the use 
of romiplostim and eltrombopag for the treatment of adults with chronic refractory 
ITP, based on annual treatment costs and cost per response. The average body weight 
adopted was 74,6 kg. Efficacy data were obtained from the product inserts, as well 
as from scientific publications. In cost per response, it was considered a 6-month 
analysis, which corresponds to the overall platelet response in clinical trials. The 
outcome of these trials was the global response to treatment. The cost of each drug 
presentation were based on ex-factory price (VAT 18%) and obtained from the official 
price list (CMED; April, 2014). Results: The cost of treatment with romiplostim 
showed an annual saving of R$7,724 over eltrombopag within the payer perspec-
tive, which may be further improved if we assume that drug-food interactions of 
eltrombopag in some patients lead to reduced medication adherence and loss of 
response. The cost per response with romiplostim was 26% lower than with eltrom-
bopag. cOnclusiOns: Romiplostim was more cost-effective than eltrombopag for 
the treatment of chronic refractory ITP in adult patients and may represent savings 
to the Brazilian health system.
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Objectives: This study evaluated the impact of BMI category on health utilities, 
health care resource-utilisation, productivity, activity impairment, and associated 
costs. MethOds: Results were from the 2013 EU5 National Health and Wellness 
Survey (N= 62,000), a nationally representative, online survey of respondents 
aged ≥ 18 years. This analysis focused on normal weight (BMI≥ 18.5 & < 25 kg/m2), 
overweight (BMI≥ 25 & < 30 kg/m2), obese class (OC) I (BMI≥ 30 & < 35 kg/m2), OC II 
(BMI≥ 35 & < 40 kg/m2), and OC III (BMI≥ 40 kg/m2) respondents. Patients provided 
information on SF-6D (health utility) scores, productivity loss (Work Productivity and 
Activity Impairment questionnaire) and resource-utilisation (type/number of visits) 
in the past six months. Direct and indirect costs were estimated from the literature. 
Generalised linear models predicted resource use and productivity as a function of 
BMI category, adjusting for covariates (e. g., age, gender, comorbidities). Results: 
Among 58,364 respondents, 46.9% were normal weight, 34.5% were overweight, 
12.5% were OC I, 4.0% were OC II, and 2.1% were OC III. Metabolic comorbidities 
increased as BMI increased. Adjusting for covariates, health utility (normal weight: 
0.720; overweight: 0.718; OC I: 0.703; OC II: 0.683; OC III: 0.662) scores declined with 
an increase in BMI (all p< 0.05 vs. normal). Among employed patients (57.7%), overall 
work impairment increased as BMI increased (normal weight: 17.9%; overweight: 
18.4%; OC I: 19.0%; OC II: 21.4%; OC III: 26.7%, p< 0.05 all OCs vs. normal). Normal 
Objectives: The aim of this study was to assess the indirect costs associated with 
multiple sclerosis (MS) from the perspective of Social Insurance Institution (ZUS) 
in Poland. MethOds: The estimates were based on data from the Social Insurance 
Institution (ZUS) referring to year 2012 and focused on absenteeism due to the 
illness: costs of sick leave as well as the short-term disability due to rehabilitation 
benefit and the burden of permanent (or long term) disability due to disability pen-
sion in Poland. Cost analysis was performed based on the Human Capital Approach 
taking into account Gross Domestic Product (GDP) per capita equaled 41 398 PLN 
and Gross Value Added (GVA) per worker equaled 99 697 PLN. Costs were presented 
in polish zloty (PLN). Results: Total indirect costs of multiple sclerosis associ-
ated with absenteeism in the year 2012 in Poland were 39 870 385 PLN calculated 
using GDP per capita and 96 018 323 PLN as a GVA per worker. The predominant 
component of absenteeism of MS was sick leave, which accounted for 69%. Long 
and short term disability costs constituted 21% and 9% of total indirect costs of 
multiple sclerosis associated with absenteeism, respectively. One sick leave of 
person with multiple sclerosis generated the cost of lost productivity equal 1 866 
PLN and 4 490 PLN calculated using GDP per capita and GVA per worker, respec-
tively. Indirect cost of short-term disability for one entitlement to the benefit of 
rehabilitation were 17 077 PLN and 41 125 PLN, respectively. Cost of one long term 
benefit were much higher than short term benefit and equaled 41 398 PLN and 99 
697 PLN, respectively. cOnclusiOns: Multiple sclerosis in Poland generated very 
high indirect costs. The main component was sick leave; disability pension and 
rehabilitation benefit generated lower costs of lost productivity.
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Objectives: The aim of this study was to assess the indirect costs caused by absen-
teeism associated with ankylosing spondylitis (AS) from the perspective of the Social 
Insurance Institution (ZUS) in Poland. MethOds: The estimates were based on data 
provided by ZUS referring to year 2012 and concerning absence from work due to 
the illness (sick leave), the amount of short term disability, the sufferers of which 
claim rehabilitation benefit, and the amount of permanent (or long term) disability, 
the sufferers of which claim disability pension. Costs were calculated with Human 
Capital Approach methodology taking into account Gross Domestic Product (GDP) 
per capita equaled 41 398PLN and Gross Value Added (GVA) per worker equaled 99 
697PLN and were presented in 2012 prices in Polish zloty (PLN). Results: Total 
indirect costs of AS in the year 2012 calculated using GDP per capita and GVA per 
worker in Poland were 21 299 578PLN and 51 294 959PLN, respectively. The high-
est component of indirect costs of AS was sick leave (56%). Long and short term 
disability costs constitute 6% and 39% of total indirect costs of AS, respectively. In 
2012 Poland’s Social Insurance Institution database reported 3 500 patients on sick 
leave, 72 patients with short term disability and 7 patients with long term disability. 
Indirect costs per patient associated with sick leave were 3 400PLN and 8 188PLN 
calculated using GDP per capita and GVA per worker, respectively. Indirect costs 
per patient associated with short term disability were 16 602PLN and 39 983PLN 
respectively and associated with long term disability were as high as 1 171 958PLN 
and 2 822 381PLN, respectively. cOnclusiOns: AS in Poland generated high indirect 
costs. The main component was sick leave; rehabilitation benefit and disability 
pension generated lower costs of lost productivity.
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Objectives: To assess the direct and indirect costs of systemic lupus erythema-
tosus (SLE), analysis of which is complex due to the heterogeneity of the disease, 
accumulative organ damage and associated comorbidities. MethOds: Direct and 
indirect costs attributable to SLE were extracted from studies published January 
2004–March 2013, identified using Medline, EMBASE, EconLit and NHS EED. Eligible 
studies involved adults with active SLE. Results: The direct cost associated with 
SLE management was € 3,691/yr in Europe.1 In the US, annual health care costs 
were $10,984 higher for SLE patients vs non-SLE controls.2 Organ damage and 
disease activity were key drivers of annual cost variations;1–4 in Europe, cardio-
vascular/respiratory (€ 596/yr) and renal involvement (€ 511/yr) appeared the most 
costly organs.1 Estimated direct annual cost of treating any flare in the EU was 
~€ 399, whilst for severe flares was ~€ 1,002.1 In the US, renal involvement was the 
most costly organ: cost ratios were 3.1 (95% CI: 2.3–4.2) in newly diagnosed and 2.7 
(95% CI: 2.4–3.0) in existing SLE patients.4 Annual costs for mild and severe flares 
in the US were $129/flare and $11,716/flare, respectively.2 The indirect economic 
burden is also substantial, as SLE typically occurs during the peak of working 
years and in young women with child-bearing potential (around the age of 20 in 
Black females and 30 in White females).5,6 Predictors of future work loss in SLE 
included older age, shorter job tenure, thrombotic and musculoskeletal manifes-
tations, greater number of manifestations and high disease.7,8 cOnclusiOns: 
The direct and indirect economic burden is prominent within SLE patients. Organ 
damage is a substantial “hidden cost” and should be considered when assessing 
the economic impact 
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a patient on LTP with recurrent bleedings. MethOds: A cost-consequences analysis 
was adopted to assess the economic impact from the NHS and Society perspectives. 
The cost analysis was based on one patient case (type 1 VWD, recurrent gum bleed-
ings), treated with FVIII/VWF and then with VWF concentrate almost devoid of FVIII. 
The costs included direct costs (drug acquisition, hospital admissions, outpatient 
visits, red blood cells units) and indirect costs (working days lost). Data were gathered 
from a questionnaire (Hemophilia Reference Center of Catania). The health care costs 
were calculated by DRG analysis that assessed DRG refund value for day hospital 
and standard hospitalization. The indirect costs were calculated on the basis of the 
annual income average. Results: The analysis showed a reduction of the number 
of bleedings when treating with VWF concentrate almost devoid of FVIII (30 vs 0), 
minimizing the cost per bleeding episodes (€ 87,957 vs € 0), hospitalizations (€ 3,252 vs 
0), monitoring visits (€ 331 vs € 165) and the number of working days lost (26 vs 2). The 
annual health care costs and indirect costs avoided were € 49,684 and € 3,734 respec-
tively. cOnclusiOns: The replacement therapy with VWF concentrate almost devoid 
of FVIII decreased the consumption of hospital resources and reduced the number 
of working days lost per bleedings together with the discomfort related to bleedings.
PSY52
CoST Per reSPonSe AnALYSiS for ThromBoPoieTin reCePTor 
AGoniSTS (TPo-rAS), in The TreATmenT of AduLT ChroniC immune 
ThromBoCYToPeniA (iTP) in mexiCo
Alva M.E.1, Rivera R.1, Arocho R.2, Campos I.3, Campioni M.4
1Amgen, Mexico City, Mexico, 2Amgen, Inc., Barcelona, Spain, 3Amgen, Zug, Switzerland, 4Amgen 
(Europe) GmbH, Zug, Switzerland
Objectives: TPO-RAs, represent an evidence-based treatment option in the pub-
lic setting for adult patients with chronic ITP in Mexico. TPO-RAs have not been 
directly compared in head-to-head randomized controlled trials (RCTs); however 
an indirect comparison was undertaken using Bayesian metaregression: the overall 
platelet response was significantly higher in patients receiving Romiplostim than 
in those receiving Eltrombopag, estimating an Odds ratio (OR) of eltrombopag vs 
romiplostim as 0.15 (95% CI: 0.02, 0.84). The objective of this study is to compare 
the cost per response of TPO-RAs in chronic adult ITP in Mexico. MethOds: A cost 
per response analysis was developed. Dose was derived from RCTs and Summary 
of Product Characteristics. Median dose for romiplostim was 2.5 mcg/kg/week and 
average dose for eltrombopag was 55 mg/day (21.5% of patients received 25mg; 
41% 75mg; and remaining 37.5% 50mg). Costs for romiplostim were based on vials 
used, considering a representative Mexican patient (65kg); for eltrombopag, it was 
based on milligrams needed. Cost assessment included cost of medication, cost of 
administration and in case of eltrombopag, cost of liver monitoring, expressed in 
Mexican pesos. Crude Overall Response Rate (ORR) for romiplostim was 83%. Placebo 
adjusted ORR for eltrombopag was 42% calculated by applying the OR estimated 
from the Bayesian indirect comparison performed by the NICE Evidence Review 
Group. Results: Romiplostim generates a cost per overall platelet response of 
$219,690.80, while eltrombopag yields $374,137.72. cOnclusiOns: Within the TPO-
RAs, romiplostim generates a lower cost per response than eltrombopag, in adult 
patients with chronic ITP in Mexico.
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Objectives: Belimumab is a novel biological treatment specifically developed for 
the treatment of active, autoantibody positive SLE patients. The purpose of this study 
is to estimate the cost-effectiveness of belimumab for SLE patients from the Spanish 
societal perspective. MethOds: A UK cost-effectiveness microsimulation model 
was adapted to the Spanish setting. The analysis compared standard of care (SoC) 
vs. belimumab plus SoC with 2 years maximum treatment duration and a life-time 
horizon. Disease activity reduction seen with belimumab in the BLISS-52 and BLISS-
76 trials, was extrapolated using data from the US Johns Hopkins Lupus Cohort to 
predict impact on long-term organ damage and mortality.. Utility values and unit 
direct costs (treatment, administration, patient´s follow-up and organ damage costs) 
were obtained from UK and Spain published data, respectively. Indirect costs were 
calculated using the Human Capital Approach method. A discount rate of 3% was 
applied to costs and outcomes. Results were expressed as € 2014. Deterministic and 
probabilistic sensitivity analyses (PSA) were conducted to determine the robust-
ness of the results. An additional analysis was conducted to compare societal and 
Spanish National Health System (NHS) perspectives. Results: The cost per life year 
gained (ICER) and cost per QALY (ICUR) for Belimumab were € 16,647 and € 23,158 
respectively. In 68% of scenarios plotted in the PSA, belimumab was a cost-effective 
alternative considering a € 30,000/QALY threshold. From NHS perspective (indirect 
costs excluded), ICER and ICUR were € 25.619 and € 35.640. cOnclusiOns: Base-case 
results show that belimumab is cost-effective from the Spanish societal perspective. 
From the NHS perspective, the model provides results that fall within an acceptable 
threshold considering the prevalence and the severity of the disease. These results 
highlight the importance of adopting a societal perspective, especially in pathologies 
such as SLE which affect young people of working age.
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Objectives: Evaluate the efficiency of rituximab in maintenance treatment of 
patients with follicular lymphoma (FL) who respond to first line induction with 
rituximab versus observation in Portugal. MethOds: Cost-effectiveness (Life 
(vs. all OCs) had lower activity impairment and fewer provider visits, lower indirect 
costs (normal weight: € 7,974; overweight: € 7,825; OC I: € 8,465; OC II: € 9,394; OC III: 
€ 10,437), and lower total direct costs (normal weight: € 516; overweight: € 553; OC I: 
€ 583; OC II: € 605; OC III: € 717), all p< 0.05. cOnclusiOns: Increased BMI is associ-
ated with higher direct and indirect costs and worse health utilities. The findings 
highlight the impact of obesity on health outcomes.
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Objectives: Autosomal dominant polycystic kidney disease (ADPKD) is the most 
common genetic kidney disease. Currently there is little published information on 
medical resource utilisation (MRU) in European ADPKD patients. This study aimed 
to estimate the health care resource use of ADPKD patients across six European 
countries. MethOds: A retrospective review of medical charts was conducted via 
an online physician survey in France, Germany, Italy, Spain, Sweden and the United 
Kingdom (UK). A total of 353 physicians were recruited to review MRU over the previ-
ous 24 month period from the records of 1,055 patients, with each clinician selecting 
the last three patients representing three different chronic kidney disease stages. 
Data collected included patient characteristics and MRU such as tests, visits, hospi-
talisations and medications. Results: The proportion of patients who had a kidney 
ultrasound during the 24 months study period varied from 20.0% in Sweden to 68.0% 
in Germany. In all countries, except Germany (66.0%), at least 90% of patients had 
one or more contact with a specialist. Annualised specialist visits varied from 2.7 
(SD 7.9) in Germany to 6.0 (SD 10.7) in Sweden. Germany had the largest proportion 
of patients with hospitalisations related to ADPKD (25.7%) whereas Sweden had 
the lowest (13.3%). Hospital length of stay was longest in Spain (mean, 8.5 days (SD 
6.2)) and shortest in the UK (mean, 4.7 days (SD 3.8)). In terms of medication use, 
32.7% of German patients were prescribed loop diuretics whereas this proportion 
was 9.0% in the UK. The UK had the highest rate of opioid use for renal pain overall 
(8.7%) and among patients on dialysis (27.3%). cOnclusiOns: This is the first study 
to provide comparative evidence on MRU in European patients with ADPKD. Results 
highlight some country-specific differences in treatment patterns, including rates 
of hospitalisation, frequency of specialist visits and medication use.
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Objectives: Autosomal dominant polycystic kidney disease (ADPKD) is the most 
common type of polycystic kidney disease (PKD) and the fourth leading cause of end-
stage renal disease. Currently, there is no published information on medical resource 
utilisation (MRU) in patients with ADPKD in Europe. This study aimed to better 
understand MRU associated with ADPKD by disease stage in six European countries 
(Germany, France, the United Kingdom, Italy, Spain and Sweden). MethOds: This 
study was a retrospective review of medical charts collected via an online physician 
survey. Participating physicians abstracted data for the last three eligible ADPKD 
patients treated in their practice, each within a different Chronic Kidney Disease 
(CKD) stage. Data collected over the past 2 years included socio-demographics, 
clinical characteristics and MRU, such as diagnostic tests, specialist visits, dialysis, 
emergency department visits, inpatient admissions and medications. Results: 
A total of 1,055 ADPKD patients were enrolled. The mean (SD) age of the sample 
was 50.4 (14.4) years, 53.6% were male, with 39.4% employed full time. Only 40% of 
patients had a known PKD genotype, of which 83% had PKD-1 and 17% had PKD-
2. Almost all patients (99.1%) experienced at least 1 ADPKD-related complication, 
most commonly hypertension (75.4%). On average (SD), patients had 4.4 (9.3) annual 
specialist visits. Approximately 19.7% of patients experienced at least 1 hospitalisa-
tion over the 2 year study period with a mean (SD) length of stay of 7.0 (8.5) days. 
Patients in more advanced disease stages reported higher mean (SD) annual spe-
cialist visits and more disease-related hospitalisations, 1.5 (1.1) and 9.2% in CKD 
Stage 1 compared to 10.0 (17.2) and 32.4% in Dialysis, respectively. cOnclusiOns: 
This is the first study to provide evidence on MRU among patients with ADPKD in 
Europe. Results demonstrate that ADPKD patients require substantial MRU, which 
accumulate with disease progression.
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Objectives: Von Willebrand Disease (VWD) is the most common inherited bleeding 
disorder, caused by a deficiency or abnormality of the Von Willebrand factor (VWF). 
Long-term prophylaxis (LTP) with Factor VIII-containing VWF product (FVIII/VWF) is 
used for patients with severe VWD. However, FVIII/VWF is not enough effective in 
some cases. Furthermore repeated infusions of FVIII/VWF may increase the risk of 
thromboembolic events. The objective of the analysis was to assess the economic 
impact of VWF concentrate almost devoid of FVIII as an alternative to FVIII/VWF for 
